FBR Capital Remains Bullish on Advaxis (ADXS) Following Conference Call About FDA IND Clinical Hold
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
